Brokerages forecast that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aeglea BioTherapeutics’ earnings. Aeglea BioTherapeutics posted earnings of ($0.47) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 42.6%. The firm is scheduled to report its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Aeglea BioTherapeutics will report full year earnings of ($2.41) per share for the current year. For the next year, analysts forecast that the firm will report earnings of ($2.37) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Aeglea BioTherapeutics.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Aeglea BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. ValuEngine lowered shares of Aeglea BioTherapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th.

Aeglea BioTherapeutics (NASDAQ AGLE) traded up 4.641% during midday trading on Tuesday, hitting $5.975. 150,127 shares of the stock traded hands. The firm’s 50-day moving average is $4.46 and its 200-day moving average is $4.77. The company’s market cap is $98.30 million. Aeglea BioTherapeutics has a 52-week low of $2.81 and a 52-week high of $10.34.

WARNING: “Zacks: Analysts Anticipate Aeglea BioTherapeutics, Inc. (AGLE) to Post -$0.67 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/10/zacks-analysts-anticipate-aeglea-biotherapeutics-inc-agle-to-post-0-67-eps.html.

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in Aeglea BioTherapeutics in the first quarter worth about $157,000. Renaissance Technologies LLC purchased a new stake in Aeglea BioTherapeutics in the first quarter worth about $270,000. Vanguard Group Inc. lifted its stake in Aeglea BioTherapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 12,966 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in Aeglea BioTherapeutics in the second quarter worth about $653,000. 48.10% of the stock is owned by institutional investors.

Aeglea BioTherapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea BioTherapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.